"Orphan Drug Production" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Production of drugs or biologicals which are unlikely to be manufactured by private industry unless special incentives are provided by others.
| Descriptor ID |
D009965
|
| MeSH Number(s) |
J01.576.655.750.600
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Orphan Drug Production".
Below are MeSH descriptors whose meaning is more specific than "Orphan Drug Production".
This graph shows the total number of publications written about "Orphan Drug Production" by people in this website by year, and whether "Orphan Drug Production" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2012 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Orphan Drug Production" by people in Profiles.
-
Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs. J Gen Intern Med. 2020 09; 35(9):2629-2636.
-
Progesterone for Prevention of Preterm Birth: Shortcomings and Unintended Consequences of the Orphan Drug Act. Obstet Gynecol. 2017 12; 130(6):1202-1206.
-
Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle Nerve. 2016 Feb; 53(2):165-8.
-
Orphan drug designation for pracinostat, volasertib and alvocidib in AML. Leuk Res. 2014 Aug; 38(8):862-5.
-
The many vs. the few. Hastings Cent Rep. 2012 Sep-Oct; 42(5):7; author reply 8-9.
-
The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS One. 2012; 7(2):e31894.
-
Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol. 2009 Sep 10; 27(26):4398-405.
-
Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007; 23(1):36-42.
-
Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med. 2006 Jan; 3(5):e102.
-
Methadone: an orphan drug? J Palliat Med. 2004 Feb; 7(1):73-4.